Shares of Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB – Get Free Report) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.00 and traded as high as $0.32. Hemispherx BioPharma shares last traded at $0.27, with a volume of 1,527,490 shares.
Hemispherx BioPharma Trading Down 8.2 %
Hemispherx BioPharma Company Profile
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
Recommended Stories
- Five stocks we like better than Hemispherx BioPharma
- 3 Tickers Leading a Meme Stock Revival
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- Consumer Staples Stocks, Explained
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- What is the FTSE 100 index?
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.